Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000285863 is classified as a long non-coding RNA (lncRNA), named "Novel transcript, antisense to VPS13C." It is annotated in genome databases as an RNA gene located antisense to the VPS13C gene. This entry does not correspond to a protein-coding gene, receptor, enzyme, transporter, or other established therapeutic target category. The label "novel transcript" indicates it is a newly annotated RNA, often with uncharacterized function, and "antisense to VPS13C" means its genomic locus is on the DNA strand opposite the VPS13C gene. There is currently no evidence or annotation supporting a protein product, functional biology, involvement in disease, or status as a therapeutic target. No alternative names, molecular functions, biological roles, interacting drugs, disease associations, or biomarker roles have been confirmed or documented for this transcript in public gene resources or literature. Given the lack of curation and unclear status, this entry is likely not suitable as a canonical molecular target and may reflect incomplete or predicted genomic annotation rather than a validated biological entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to VPS13C (ENSG00000285863).